Literature DB >> 25287691

Molecular imaging of the tumor microenvironment for precision medicine and theranostics.

Marie-France Penet1, Balaji Krishnamachary2, Zhihang Chen2, Jiefu Jin2, Zaver M Bhujwalla3.   

Abstract

Morbidity and mortality from cancer and their associated conditions and treatments continue to extract a heavy social and economic global burden despite the transformative advances in science and technology in the twenty-first century. In fact, cancer incidence and mortality are expected to reach pandemic proportions by 2025, and costs of managing cancer will escalate to trillions of dollars. The inability to establish effective cancer treatments arises from the complexity of conditions that exist within tumors, the plasticity and adaptability of cancer cells coupled with their ability to escape immune surveillance, and the co-opted stromal cells and microenvironment that assist cancer cells in survival. Stromal cells, although destroyed together with cancer cells, have an ever-replenishing source that can assist in resurrecting tumors from any residual cancer cells that may survive treatment. The tumor microenvironment landscape is a continually changing landscape, with spatial and temporal heterogeneities that impact and influence cancer treatment outcome. Importantly, the changing landscape of the tumor microenvironment can be exploited for precision medicine and theranostics. Molecular and functional imaging can play important roles in shaping and selecting treatments to match this landscape. Our purpose in this review is to examine the roles of molecular and functional imaging, within the context of the tumor microenvironment, and the feasibility of their applications for precision medicine and theranostics in humans.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Molecular imaging; Precision medicine; Theranostics; Tumor microenvironment

Mesh:

Year:  2014        PMID: 25287691      PMCID: PMC4332825          DOI: 10.1016/B978-0-12-411638-2.00007-0

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  69 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  Ovarian carcinoma: quantitative biexponential MR imaging relaxometry reveals the dynamic recruitment of ferritin-expressing fibroblasts to the angiogenic rim of tumors.

Authors:  Moriel H Vandsburger; Marina Radoul; Yoseph Addadi; Senzeni Mpofu; Batya Cohen; Raya Eilam; Michal Neeman
Journal:  Radiology       Date:  2013-06-25       Impact factor: 11.105

3.  Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.

Authors:  Cristina Grange; Simonetta Geninatti-Crich; Giovanna Esposito; Diego Alberti; Lorenzo Tei; Benedetta Bussolati; Silvio Aime; Giovanni Camussi
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

Review 4.  Hypoxia and adaptive landscapes in the evolution of carcinogenesis.

Authors:  Robert J Gillies; Robert A Gatenby
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

5.  Longitudinal study of tumor-associated macrophages during tumor expansion using MRI.

Authors:  Yen-Yu I Shih; Yi-Hua Hsu; Timothy Q Duong; Sui-Shan Lin; Kai-Ping N Chow; Chen Chang
Journal:  NMR Biomed       Date:  2011-03-24       Impact factor: 4.044

6.  In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors.

Authors:  Daniel Procissi; Filip Claus; Paul Burgman; Jacek Koziorowski; J Donald Chapman; Sunitha B Thakur; Cornelia Matei; C Clifton Ling; Jason A Koutcher
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

7.  Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.

Authors:  Alexander M Spence; Mark Muzi; Kristin R Swanson; Finbarr O'Sullivan; Jason K Rockhill; Joseph G Rajendran; Tom C H Adamsen; Jeanne M Link; Paul E Swanson; Kevin J Yagle; Robert C Rostomily; Daniel L Silbergeld; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

8.  Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles.

Authors:  Anne H Schmieder; Patrick M Winter; Todd A Williams; John S Allen; Grace Hu; Huiying Zhang; Shelton D Caruthers; Samuel A Wickline; Gregory M Lanza
Journal:  Radiology       Date:  2013-06-14       Impact factor: 11.105

9.  Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules.

Authors:  Makoto Mitsunaga; Mikako Ogawa; Nobuyuki Kosaka; Lauren T Rosenblum; Peter L Choyke; Hisataka Kobayashi
Journal:  Nat Med       Date:  2011-11-06       Impact factor: 53.440

Review 10.  Development of HIF-1 inhibitors for cancer therapy.

Authors:  Barbara Onnis; Annamaria Rapisarda; Giovanni Melillo
Journal:  J Cell Mol Med       Date:  2009-08-08       Impact factor: 5.310

View more
  23 in total

1.  Using semi-quantitative dynamic contrast-enhanced magnetic resonance imaging parameters to evaluate tumor hypoxia: a preclinical feasibility study in a maxillofacial VX2 rabbit model.

Authors:  Linfeng Zheng; Yujie Li; Feng Geng; Sujuan Zheng; Ruiling Yan; Yuedong Han; Qiben Wang; Zhuoli Zhang; Guixiang Zhang
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

2.  Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis.

Authors:  Mojtaba Ghasemi; Iraj Nabipour; Abdolmajid Omrani; Zeinab Alipour; Majid Assadi
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-11-30

3.  In vivo molecular imaging of colorectal cancer using quantum dots targeted to vascular endothelial growth factor receptor 2 and optical coherence tomography/laser-induced fluorescence dual-modality imaging.

Authors:  Jordan L Carbary-Ganz; Weston A Welge; Jennifer K Barton; Urs Utzinger
Journal:  J Biomed Opt       Date:  2015       Impact factor: 3.170

4.  Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy.

Authors:  Min Zhou; Marites Melancon; R Jason Stafford; Junjie Li; Alpa M Nick; Mei Tian; Anil K Sood; Chun Li
Journal:  J Nucl Med       Date:  2016-06-09       Impact factor: 10.057

Review 5.  Tumor Microenvironment Biosensors for Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopy.

Authors:  Changhua Mu; David E Korenchan; Sinan Wang; David M Wilson; Robert R Flavell
Journal:  Mol Imaging Biol       Date:  2021-01-07       Impact factor: 3.484

Review 6.  The Utility of Molecular Imaging in Prostate Cancer.

Authors:  Aaron Leiblich; Daniel Stevens; Prasanna Sooriakumaran
Journal:  Curr Urol Rep       Date:  2016-03       Impact factor: 3.092

Review 7.  Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging.

Authors:  Nirilanto Ramamonjisoa; Ellen Ackerstaff
Journal:  Front Oncol       Date:  2017-01-31       Impact factor: 6.244

8.  Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer.

Authors:  Zheng Han; Xiaohui Wu; Sarah Roelle; Chuheng Chen; William P Schiemann; Zheng-Rong Lu
Journal:  Nat Commun       Date:  2017-09-25       Impact factor: 14.919

9.  Targeted Radiosensitizers for MR-Guided Radiation Therapy of Prostate Cancer.

Authors:  Dong Luo; Andrew Johnson; Xinning Wang; Hao Li; Bernadette O Erokwu; Sarah Springer; Jason Lou; Gopalakrishnan Ramamurthy; Chris A Flask; Clemens Burda; Thomas J Meade; James P Basilion
Journal:  Nano Lett       Date:  2020-08-31       Impact factor: 12.262

Review 10.  Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid.

Authors:  Gianfranco Baronzio; Gurdev Parmar; Miriam Baronzio
Journal:  Front Oncol       Date:  2015-07-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.